First-line crizotinib versus pemetrexed–cisplatin or pemetrexed–carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014)
Tony Mok
Consultant or Advisory Role - Amgen; AstraZeneca; AVEO; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis; Eisai; GlaxoSmithKline; Janssen; Lilly; Merck Serono; Pfizer; Roche; Taiho Pharmaceutical
Honoraria - Amgen; AstraZeneca; AVEO; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis; Eisai; GlaxoSmithKline; Janssen; Lilly; Merck Serono; Pfizer; Roche; Taiho Pharmaceutical
Research Funding - AstraZeneca
Dong-Wan Kim
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Yi-Long Wu
Honoraria - AstraZeneca; Lilly; Roche
Benjamin J. Solomon
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Research Funding - Pfizer
Kazuhiko Nakagawa
Honoraria - Lilly; Pfizer
Research Funding - Lilly; Pfizer
Tarek Mekhail
Consultant or Advisory Role - Pfizer
Honoraria - Lilly; Pfizer
Research Funding - Lilly; Pfizer; Roche
Enriqueta Felip
Consultant or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Novartis; Roche
Federico Cappuzzo
Consultant or Advisory Role - Pfizer; Roche
Honoraria - Pfizer; Roche
Jolanda Paolini
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Tiziana Usari
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Jennifer Tursi
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Fiona Helen Blackhall
Consultant or Advisory Role - Lilly (U); Pfizer (U)
Honoraria - Lilly; Pfizer
Research Funding - Lilly; Pfizer
Expert Testimony - Pfizer (U)